Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
NCT04676048

ASC618 Gene Therapy in Hemophilia A Patients

Led by ASC Therapeutics · Updated on 2023-02-01

12

Participants Needed

1

Research Sites

225 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, encourage the current efforts for gene transfer therapy. This study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed promoter

CONDITIONS

Official Title

ASC618 Gene Therapy in Hemophilia A Patients

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 18 years or older
  • Severe or moderately severe hemophilia A with factor VIII activity ≤ 2 IU/dL
  • Medical history confirming hemophilia A diagnosis
  • Received at least 150 days of factor VIII prophylactic or on-demand replacement therapy
  • At least 12 bleeding episodes in the past 12 months if on on-demand therapy
  • Body mass index (BMI) of 30 or less
  • Agree to use double-barrier contraception until three consecutive semen samples test negative after ASC618 infusion
Not Eligible

You will not qualify if you...

  • Pre-existing immunity to AAV8 vector as shown by antibody tests
  • Current inhibitors or history of high titer factor VIII inhibitors
  • Liver fibrosis greater than Grade 2 based on imaging tests
  • History of chronic kidney disease
  • Active infection or immunosuppressive disorder
  • History of heart surgery and need for anticoagulant therapy
  • Cardiovascular or genetic risk factors for blood clots
  • Active infections with Hepatitis B, Hepatitis C, HIV-1/2, or syphilis
  • Previous treatment with any vector or gene transfer agent
  • Current antiviral treatment for Hepatitis B or C

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

Loading map...

Research Team

C

Clinical Trial Manager, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here